Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd. has reached a new 52-week low, with its stock price falling to Rs.659.55 today. This marks a significant decline amid broader market fluctuations and ongoing sector pressures, reflecting a challenging period for the company within the Pharmaceuticals & Biotechnology industry.

Alembic Pharmaceuticals Ltd. has reached a new 52-week low of Rs.665.1 today, marking a significant decline in its stock price amid a series of consecutive falls and underperformance relative to its sector and benchmark indices.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Alembic Pharmaceuticals Ltd. has reached a new 52-week low of Rs.670.35, marking a significant decline amid a challenging market environment and subdued company performance. The stock has been on a downward trajectory over the past several sessions, reflecting broader sector pressures and company-specific factors.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Alembic Pharmaceuticals Ltd. has reached a new 52-week low of Rs.671 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its recent financial performance and valuation metrics.

Alembic Pharmaceuticals Ltd. has reached a new 52-week low of Rs.725.3 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance factors. This level represents a notable drop from its 52-week high of Rs.1107.8, reflecting ongoing challenges in both long-term and recent financial metrics.

Alembic Pharmaceuticals Ltd. has reached a new 52-week low of Rs.725.45, marking a significant decline amid a broader market environment where the Sensex has shown mixed performance. The stock has underperformed its sector and key benchmarks, reflecting ongoing concerns about its recent financial results and valuation metrics.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Alembic Pharmaceuticals Ltd. has reported a flat financial performance for the quarter ended December 2025, marking a notable shift from its previously positive growth trajectory. Despite a 21.0% increase in quarterly profit after tax (PAT), other key financial indicators such as earnings per share (EPS) and inventory turnover have shown signs of strain, prompting a downgrade in the company’s Mojo Grade from Hold to Sell as of 25 Nov 2025.

Alembic Pharmaceuticals Ltd. reported a concerning 28.01% quarter-on-quarter decline in consolidated net profit for Q3 FY26, with earnings falling to ₹132.97 crores from ₹184.71 crores in Q2 FY26. The Vadodara-based pharmaceutical manufacturer, with a market capitalisation of ₹15,922 crores, witnessed its stock trading at ₹801.70 following the results announcement, reflecting investor disappointment with the sequential deterioration in profitability despite modest year-on-year growth of 10.84% in net sales.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date perspective on the company’s performance and outlook.